Browse CXCL14

Summary
SymbolCXCL14
Namechemokine (C-X-C motif) ligand 14
Aliases BRAK; NJAC; bolekine; Kec; MIP-2g; BMAC; breast and kidney; SCYB14; small inducible cytokine subfamily B (Cy ......
Chromosomal Location5q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted.
Domain PF00048 Small cytokines (intecrine/chemokine)
Function

Potent chemoattractant for neutrophils, and weaker for dendritic cells. Not chemotactic for T-cells, B-cells, monocytes, natural killer cells or granulocytes. Does not inhibit proliferation of myeloid progenitors in colony formation assays.

> Gene Ontology
 
Biological Process GO:0002685 regulation of leukocyte migration
GO:0002687 positive regulation of leukocyte migration
GO:0002688 regulation of leukocyte chemotaxis
GO:0002690 positive regulation of leukocyte chemotaxis
GO:0007423 sensory organ development
GO:0030335 positive regulation of cell migration
GO:0030595 leukocyte chemotaxis
GO:0032103 positive regulation of response to external stimulus
GO:0035747 natural killer cell chemotaxis
GO:0040017 positive regulation of locomotion
GO:0042692 muscle cell differentiation
GO:0043583 ear development
GO:0045445 myoblast differentiation
GO:0045661 regulation of myoblast differentiation
GO:0045662 negative regulation of myoblast differentiation
GO:0048247 lymphocyte chemotaxis
GO:0048839 inner ear development
GO:0050900 leukocyte migration
GO:0050920 regulation of chemotaxis
GO:0050921 positive regulation of chemotaxis
GO:0051147 regulation of muscle cell differentiation
GO:0051148 negative regulation of muscle cell differentiation
GO:0051272 positive regulation of cellular component movement
GO:0060326 cell chemotaxis
GO:0072676 lymphocyte migration
GO:1901623 regulation of lymphocyte chemotaxis
GO:2000147 positive regulation of cell motility
GO:2000401 regulation of lymphocyte migration
GO:2000403 positive regulation of lymphocyte migration
GO:2000501 regulation of natural killer cell chemotaxis
GO:2000503 positive regulation of natural killer cell chemotaxis
Molecular Function GO:0001664 G-protein coupled receptor binding
GO:0005125 cytokine activity
GO:0005126 cytokine receptor binding
GO:0008009 chemokine activity
GO:0042379 chemokine receptor binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04060 Cytokine-cytokine receptor interaction
Reactome -
Summary
SymbolCXCL14
Namechemokine (C-X-C motif) ligand 14
Aliases BRAK; NJAC; bolekine; Kec; MIP-2g; BMAC; breast and kidney; SCYB14; small inducible cytokine subfamily B (Cy ......
Chromosomal Location5q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CXCL14 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolCXCL14
Namechemokine (C-X-C motif) ligand 14
Aliases BRAK; NJAC; bolekine; Kec; MIP-2g; BMAC; breast and kidney; SCYB14; small inducible cytokine subfamily B (Cy ......
Chromosomal Location5q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CXCL14 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCXCL14
Namechemokine (C-X-C motif) ligand 14
Aliases BRAK; NJAC; bolekine; Kec; MIP-2g; BMAC; breast and kidney; SCYB14; small inducible cytokine subfamily B (Cy ......
Chromosomal Location5q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CXCL14 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.5110.596
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.9970.663
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.120.932
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.630.325
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.9970.627
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.1650.948
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.2730.796
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.8230.307
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-1.3610.466
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.250.928
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.3680.93
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.2650.325
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CXCL14 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCXCL14
Namechemokine (C-X-C motif) ligand 14
Aliases BRAK; NJAC; bolekine; Kec; MIP-2g; BMAC; breast and kidney; SCYB14; small inducible cytokine subfamily B (Cy ......
Chromosomal Location5q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CXCL14. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCXCL14
Namechemokine (C-X-C motif) ligand 14
Aliases BRAK; NJAC; bolekine; Kec; MIP-2g; BMAC; breast and kidney; SCYB14; small inducible cytokine subfamily B (Cy ......
Chromosomal Location5q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CXCL14. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CXCL14.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCXCL14
Namechemokine (C-X-C motif) ligand 14
Aliases BRAK; NJAC; bolekine; Kec; MIP-2g; BMAC; breast and kidney; SCYB14; small inducible cytokine subfamily B (Cy ......
Chromosomal Location5q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CXCL14. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCXCL14
Namechemokine (C-X-C motif) ligand 14
Aliases BRAK; NJAC; bolekine; Kec; MIP-2g; BMAC; breast and kidney; SCYB14; small inducible cytokine subfamily B (Cy ......
Chromosomal Location5q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CXCL14 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCXCL14
Namechemokine (C-X-C motif) ligand 14
Aliases BRAK; NJAC; bolekine; Kec; MIP-2g; BMAC; breast and kidney; SCYB14; small inducible cytokine subfamily B (Cy ......
Chromosomal Location5q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CXCL14 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCXCL14
Namechemokine (C-X-C motif) ligand 14
Aliases BRAK; NJAC; bolekine; Kec; MIP-2g; BMAC; breast and kidney; SCYB14; small inducible cytokine subfamily B (Cy ......
Chromosomal Location5q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CXCL14 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.